DSpace Repository

Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver

Show simple item record

dc.contributor.author Bessone, Fernando
dc.contributor.author Hernández, Nelia
dc.contributor.author Tagle, Martín
dc.contributor.author Arrese, Marco
dc.contributor.author Parana, Raymundo
dc.contributor.author Méndez-Sánchez, Nahum
dc.contributor.author Ridruejo, Ezequiel
dc.contributor.author Mendizabal, Manuel
dc.contributor.author Dagher, Lucy
dc.contributor.author Contreras, Fernando
dc.contributor.author Fassio, Eduardo
dc.contributor.author Pesoa, Mario
dc.contributor.author Brahm, Javier
dc.contributor.author Silva, Marcelo
dc.date.accessioned 2021-04-13T20:50:58Z
dc.date.available 2021-04-13T20:50:58Z
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12866/9121
dc.description.abstract Idiosyncratic drug-induced liver injury (DILI) caused by xenobiotics (drugs, herbals and dietary supplements) is an uncommon cause of liver disease presenting with a wide range of phenotypes and disease severity, acute hepatitis mimicking viral hepatitis to autoimmune hepatitis, steatosis, fibrosis or rare chronic vascular syndromes. Disease severity ranges from asymptomatic liver test abnormalities to acute liver failure. DILI has been traditionally classified in predictable or intrinsic (dose-related) or unpredictable (not dose-related) mechanisms. Few prospective studies are assessing the real prevalence and incidence of hepatotoxicity in the general population. DILI registries represent useful networks used for the study of liver toxicity, aimed at improving the understanding of causes, phenotypes, natural history, and standardized definitions of hepatotoxicity. Although most of the registries do not carry out population-based studies, they may provide important data related to the prevalence of DILI, and also may be useful to compare features from different countries. With the support of the Spanish Registry of Hepatotoxicity, our Latin American Registry (LATINDILI) was created in 2011, and more than 350 DILI patients have been recruited to date. This position paper describes the more frequent drugs and herbs-induced DILI in Latin America, mainly focusing on several features of responsible medicaments. Also, we highlighted the most critical points on the management of hepatotoxicity in general and those based on findings from our Latin American experience in particular. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Annals of Hepatology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject ALEH en_US
dc.subject DILI en_US
dc.subject Hepatitis en_US
dc.subject Hepatotoxicity en_US
dc.subject HILI en_US
dc.subject LATINDILI en_US
dc.title Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/j.aohep.2021.100321
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.19
dc.relation.issn 2659-5982


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics